ClinicalTrials.gg
TerminatedNCT02711137Updated Oct 21, 2025Results posted

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

A Phase 1/2 interventional study of INCB057643 and Gemcitabine in Solid Tumors, sponsored by Incyte Corporation. Terminated at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study terminated due to safety issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
137
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma by Incyte Corporation — 1 open to participants now, 1 under way, none of them phase 3. Lymphoma · Incyte Corporation.

Enrollment
4th of 14
137 · median 84
Started
2016
with 1 other
Phase 1/2
7 of 15
1 open now
Registered
5th of 15
by date

Among the 15 studies in Lymphoma by Incyte Corporation, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 1/2, and was the 5th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 15 studies in Lymphoma by Incyte Corporation is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with advanced malignancies.

Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types including solid tumors, lymphomas and other hematologic malignancies. Part 3 will determine the tolerated dose of INCB057643 in combination with select SOC agents; and assess the safety and tolerability of the combination therapy in select advanced solid tumors and hematologic malignancies. Part 4 will further evaluate the safety, preliminary efficacy, PK, and PD of the selected dose combination from Part 3 in 4 specific advanced solid tumor and hematologic malignancies.

03

Conditions studied

  • Solid Tumors

Keywords

  • Solid tumor
  • lymphoma
  • leukemia
  • AML
  • myelodysplastic syndrome (MDS)
  • multiple myeloma
  • myeloproliferative neoplasm (MPN)
  • MDS/MPN
  • myelofibrosis (MF)
  • pancreatic cancer
  • colorectal cancer
  • non-small cell lung cancer
  • prostate cancer
  • breast cancer
  • ovarian cancer
  • glioblastoma multiforme (GBM)
  • NUT midline carcinoma
  • non-Hodgkin lymphoma
  • diffuse large B-cell lymphoma (DLBCL)
  • double-hit
  • triple-hit
  • myc
  • bromodomain and extra-terminal (BET) inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of advanced or :

    • Part 1: solid tumors or lymphomas, or hematologic malignancies
    • Part 2: histologically confirmed disease in specific tumor types
    • Part 3: advanced solid tumor or hematologic malignancy
    • Part 4: select advanced solid tumor or hematologic malignancy
  • For Part 1 and 2, subjects must have progressed following at least 1 and there is no further established therapy that is known to provide clinical benefit (including subjects who are intolerant to the established therapy)
  • For Parts 3 and 4, subjects must have progressed following at least 1 line of prior therapy, and the treatment with the select SOC agent is relevant for the specific disease cohort.
  • > 12 weeks, for MF subjects in Parts 3 and 4, life expectancy > 24 weeks
  • (ECOG) performance status

    • Parts 1 and 3: 0 or 1
    • Parts 2 and 4: 0, 1, or 2
  • Willingness to avoid pregnancy or fathering children

Exclusion criteria

Exclusion Criteria:

  • Inadequate bone marrow function per protocol-specified , count, and
  • Inadequate organ function per protocol-specified total , and ALT, and alkaline phosphatase.
  • Receipt of anticancer medications or drugs within protocol-specified intervals
  • Unless approved by the medical monitor, may not have received an hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplant
  • Unless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatment
  • Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy
  • Radiotherapy within the 2 weeks before initiation of treatment. Palliative radiation treatment to nonindex or bone lesions performed less than 2 weeks before treatment initiation may be considered with medical monitor approval
  • Currently active and uncontrolled infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
  • Untreated brain or central nervous system (CNS) or brain/ that have progressed
  • History or presence of abnormal (ECG) that, in the investigator's opinion, is
  • Type 1 diabetes or uncontrolled Type 2 diabetes
  • of ≥ 8% (all subjects will have HbA1c test at screening)
  • Any sign of clinically significant bleeding
  • Coagulation panel within protocol-specified parameters
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Part1/Treatment Group A : 8mg QD INCB057643

    Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma

    Drug: INCB057643

  • Experimental
    Part1/Treatment Group A : 12mg QD INCB057643

    Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma

    Drug: INCB057643

  • Experimental
    Part1/Treatment Group A : 16mg QD INCB057643

    Initial cohort dose of INCB057643 monotherapy at the protocol specified starting dose in the TGA. Treatment Group A included solid tumors and lymphoma

    Drug: INCB057643

  • Experimental
    Part1/Treatment Group B : 8mg QD INCB057643

    Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF

    Drug: INCB057643

  • Experimental
    Part1/Treatment Group B : 12mg QD INCB057643

    Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group B (TGB), based on protocol-specific criteria. Treatment Group B included any acute leukemia, HRMDS, MDS/MPN, or MF.

    Drug: INCB057643

  • Experimental
    Part1/Treatment Group C : 8mg QD INCB057643

    Initial cohort dose of INCB054763 monotherapy at the protocol-specified cohort escalation treatment group C (TGC), based on protocol-specific criteria. Treatment Group C includes subjects with MM

    Drug: INCB057643

  • Experimental
    Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort

    Initial cohort dose of INCB054763 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group A (TGA), based on protocol-specific criteria. Part 2 Treatment Group A expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.

    Drug: INCB057643

  • Experimental
    Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort

    Initial cohort dose of INCB057463 monotherapy at the specified RP2D dose selected in Part 1 cohort escalation treatment group B (TGB), based on protocol-specific criteria. Part 2 Treatment Group B expansion included pancreatic adenocarcinoma, castration-resistant prostrate cancer, breast cancer, high grade serious ovarian cancer, glioblastoma multiform, non-hodgkin's lymphoma, ewing's sarcoma, and solid tumor or lymphoma.

    Drug: INCB057643

  • Experimental
    Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg

    Initial cohort dose of INCB057643 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Gemcitabine) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies where Gemcitabine is relevant

    Drug: INCB057643 · Drug: Gemcitabine

  • Experimental
    Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg

    Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Paclitaxel) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.

    Drug: INCB057643 · Drug: Paclitaxel

  • Experimental
    Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg

    Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Rucaparib) in relapsed or refractory advanced or metastatic solid tumors and hematologic malignancies.

    Drug: INCB057643 · Drug: Rucaparib

  • Experimental
    Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni

    Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Abiraterone + Prednisone) in Castration Resistant Prostrate Cancer

    Drug: INCB057643 · Drug: Abiraterone

  • Experimental
    Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg

    Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Ruxolitinib) in Myelofibrosis.

    Drug: INCB057643 · Drug: Ruxolitinib

  • Experimental
    Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg

    Initial cohort dose of INCB054763 monotherapy based on protocol-specific criteria. Part 3 will determine the MTD and/or a tolerated dose of the combination of INCB057643 and one of the SOC agents (Azacitidine) in Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Drug: INCB057643 · Drug: Azacitidine

Interventions

  • Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).

  • Standard of Care (SOC) agents

  • Standard of Care (SOC) agents

  • Standard of Care (SOC) agents

  • Standard of Care (SOC) agents

  • Standard of Care (SOC) agents

  • Standard of Care (SOC) agents

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAE's).

    Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

    Time frame: From screening through at least 30 days after end of treatment, up to approximately 24 months

Secondary outcomes

  1. Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay

    An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643.

    Time frame: PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1

  2. Objective Response Rate (ORR) With INCB057643 in Solid Tumors

    Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response \[complete response (CR) or partial response (PR)\].

    Time frame: Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months

  3. Cmax: Maximum Observed Plasma Concentration of INCB057643.

    Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8

  4. Tmax: Time to Maximum Plasma Concentration of INCB057643

    Time to maximum plasma concentration of INCB057643 administered as monotherapy in fasted state

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8

  5. AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643

    Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB057643 administered as monotherapy in fasted state

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1

  6. AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

    Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8

  7. Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.

    Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state.

    Time frame: C2D1

  8. Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643

    Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state

    Time frame: C2D1

  9. AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

    Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state.

    Time frame: C2D1

07

Results

Posted Apr 28, 2022

Participant flow

A total of 137 subjects enrolled at 19 different sites in USA.

Participant flow — Overall Study
MilestonePart1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mgEnrolled But Not Dosed
Started4587518651243123
Completed000000000000000
Not completed4587518651243123
Withdrew: Death1455316130111000
Withdrew: Study terminated by sponsor001000100000000
Withdrew: Physician decision1021101221132112
Withdrew: Other010000300000001
Withdrew: Withdrawal by subject100110700000010
Withdrew: Lost to follow-up100000200000000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE's).

Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.

Time frame:
From screening through at least 30 days after end of treatment, up to approximately 24 months
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE's).
ParticipantsPart1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg
Number of Participants With Treatment Emergent Adverse Events (TEAE's).458751865124312
SecondaryPercent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay

An ex vivo assay (utilized in monotherapy only), Measuring Total c-Myc protein expressed from an exogenously added cell line (KMS12BM) to patient plasma, before and after administration of INCB057643.

Time frame:
PD in plasma at pre-dose and 0.5, 1, 2, 4, 6 and 8 hours postdose, for C1D1 and C1D8, and 24hrs post dose for C1D1
Reported as:
Mean · %Inhibition of Total c-Myc
Percent Inhibition of Total Cellular Myc Protein Concentrations Before and After Administration of INCB057643 When Administered as Monotherapy in an Ex-vivo Assay
%Inhibition of Total c-Myc8mg QD INCB05764312mg QD INCB05764316mg QD INCB057643
C1D124 ± 199.528 ± 200.154 ± 236.3
C1D830 ± 42.5943.4 ± 52.765 ± 55.21
SecondaryObjective Response Rate (ORR) With INCB057643 in Solid Tumors

Objective response rate is defined as the proportion of subjects who have an objective response using the applicable disease assessment criteria. ORR was proportion of participants with best overall response \[complete response (CR) or partial response (PR)\].

Time frame:
Efficacy measures from screening through end of treatment and follow-up (every 9 weeks), up to approximately 24 months
Reported as:
Number · Participants
Objective Response Rate (ORR) With INCB057643 in Solid Tumors
ParticipantsPart1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg
Solid Tumors000———0—0100——
Lymphoma101———2———————
AML———00——1—————0
Glioblastoma——————0———————
Myelodysplastic Syndrome———00——0——————
Myelofibrosis———0———0————0—
Multiple Myeloma—————0————————
SecondaryCmax: Maximum Observed Plasma Concentration of INCB057643.

Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fasted state.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8
Reported as:
Mean · nM
Cmax: Maximum Observed Plasma Concentration of INCB057643.
nM8mg QD INCB05764312mg QD INCB05764316mg QD INCB057643
C1D1201 ± 83.6266 ± 94.7343 ± 93.2
C1D8210 ± 93.2293 ± 113340 ± 165
SecondaryTmax: Time to Maximum Plasma Concentration of INCB057643

Time to maximum plasma concentration of INCB057643 administered as monotherapy in fasted state

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1 and C1D8
Reported as:
Median · hours
Tmax: Time to Maximum Plasma Concentration of INCB057643
hours8mg QD INCB05764312mg QD INCB05764316mg QD INCB057643
C1D12.00 (1.00 to 24.00)2 (0.50 to 8.00)2.00 (2.00 to 4.00)
C1D81.00 (1.00 to 4.00)2 (0.50 to 8.00)2.00 (2.00 to 4.00)
SecondaryAUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643

Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration of INCB057643 administered as monotherapy in fasted state

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D1
Reported as:
Mean · h*nM
AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB057643
h*nM8mg QD INCB05764312mg QD INCB05764316mg QD INCB057643
AUC0-t: Area Under the Single-dose Plasma Concentration-time Curve of INCB0576432090 ± 50.12550 ± 39.53210 ± 34.3
SecondaryAUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fasted state

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8 hours on C1D8
Reported as:
Mean · h*nM
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
h*nM8mg QD INCB05764312mg QD INCB05764316mg QD INCB057643
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy1940 ± 45.12740 ± 43.23610 ± 71.9
SecondaryPart 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.

Maximum Observed Plasma Concentration INCB057643 administered as monotherapy in fed state.

Time frame:
C2D1
Reported as:
Mean · nM
Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.
nM12mg QD INCB057643
Part 2 - Cmax: Maximum Observed Plasma Concentration of INCB057643.220 ± 32.0
SecondaryPart 2-Tmax: Time to Maximum Plasma Concentration of INCB057643

Time to maximum plasma concentration of INCB057643 administered as monotherapy in fed state

Time frame:
C2D1
Reported as:
Median · hours
Part 2-Tmax: Time to Maximum Plasma Concentration of INCB057643
hours12mg QD INCB057643
Part 2-Tmax: Time to Maximum Plasma Concentration of INCB0576436.00 (4.00 to 8.00)
SecondaryAUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy

Area under the steady-state plasma concentration-time curve over 1 dosing interval from Hour 0 to 24 for QD administration of INCB057643 administered as monotherapy in fed state.

Time frame:
C2D1
Reported as:
Mean · h*nM
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy
h*nM12mg QD INCB057643
AUC0-24: Area Under the Steady-state Plasma Concentration-time Curve of INCB057643 Administered as Monotherapy2980 ± 31.5

Adverse events

Collected over From screening through at least 30 days after end of treatment, up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part1/Treatment Group A : 8mg QD INCB0576432/4 (50%)2/4 (50%)4/4 (100%)
Part1/Treatment Group A : 12mg QD INCB0576434/5 (80%)1/5 (20%)5/5 (100%)
Part1/Treatment Group A : 16mg QD INCB0576435/8 (62.5%)4/8 (50%)7/8 (87.5%)
Part1/Treatment Group B : 8mg QD INCB0576436/7 (85.7%)5/7 (71.4%)7/7 (100%)
Part1/Treatment Group B : 12mg QD INCB0576434/5 (80%)4/5 (80%)5/5 (100%)
Part1/Treatment Group C : 8mg QD INCB0576431/1 (100%)1/1 (100%)0/1 (0%)
Part2/Treatment Group A : 12 mg INCB057643 Expansion Cohort68/86 (79.1%)32/86 (37.2%)82/86 (95.3%)
Part2/Treatment Group B : 12 mg INCB057643 Expansion Cohort3/5 (60%)4/5 (80%)5/5 (100%)
Part3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mg0/1 (0%)0/1 (0%)1/1 (100%)
Part3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mg1/2 (50%)0/2 (0%)2/2 (100%)
Part3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mg1/4 (25%)0/4 (0%)4/4 (100%)
Part3/Treatment Group D : 8 mg INCB057643 + Abir +Predni1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mg0/1 (0%)1/1 (100%)1/1 (100%)
Part3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventPart1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg
Herpes zosterInfections and infestations0/40/50/80/70/50/10/860/50/10/20/40/31/10/2
Septic shockInfections and infestations0/40/50/80/70/51/10/860/50/10/20/40/30/10/2
Febrile neutropeniaBlood and lymphatic system disorders0/40/50/81/72/50/10/862/50/10/20/40/30/10/2
Acute kidney injuryRenal and urinary disorders0/40/50/82/70/50/11/860/50/10/20/41/30/10/2
DyspnoeaRespiratory, thoracic and mediastinal disorders0/40/50/80/70/50/12/860/50/10/20/41/30/10/2
Pleural effusionRespiratory, thoracic and mediastinal disorders0/40/51/80/70/50/10/860/50/10/20/41/30/10/2
TachycardiaCardiac disorders0/40/50/80/70/50/10/860/50/10/20/41/30/10/2
PneumoniaInfections and infestations0/40/51/82/70/50/11/861/50/10/20/40/30/10/2
Performance status decreasedGeneral disorders1/40/50/80/70/50/10/860/50/10/20/40/30/10/2
SepsisInfections and infestations1/40/50/81/70/50/14/861/50/10/20/40/30/10/2
Most frequent other events
Showing 10 of 178
Most frequent other events
EventPart1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mg
AnaemiaBlood and lymphatic system disorders0/41/53/84/73/50/115/864/50/11/22/40/31/10/2
DiarrhoeaGastrointestinal disorders1/42/53/84/71/50/121/861/50/10/22/40/31/11/2
DizzinessNervous system disorders1/41/51/80/70/50/110/861/50/10/20/40/31/10/2
FallInjury, poisoning and procedural complications0/40/51/82/71/50/14/860/50/10/20/40/31/10/2
Herpes zosterInfections and infestations1/40/51/80/70/50/15/860/50/10/20/40/31/10/2
HyperglycaemiaMetabolism and nutrition disorders2/40/53/81/70/50/113/860/50/10/20/41/31/10/2
HypertriglyceridaemiaMetabolism and nutrition disorders0/40/50/80/70/50/12/860/50/10/20/40/31/10/2
Oedema peripheralGeneral disorders0/40/50/80/70/50/12/861/50/10/20/41/31/10/2
Platelet count decreasedInvestigations1/40/50/81/72/50/18/860/50/10/21/40/31/10/2
Post herpetic neuralgiaNervous system disorders0/40/50/80/70/50/10/860/50/10/20/40/31/10/2

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mgEnrolled But Not DosedTotal
Mean64.3 ± 10.2160.2 ± 12.2660.5 ± 11.4468.9 ± 5.8175.8 ± 7.3370.0 ± NA60.6 ± 13.8072.6 ± 10.9272.0 ± 056.0 ± 12.7366.0 ± 6.1667.7 ± 4.0475.0 ± 076.5 ± 2.1266.0 ± 6.2463.0 ± 12.80
Sex: Female, Male
Sex: Female, Male(Participants)Part1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mgEnrolled But Not DosedTotal
Female225310480114000168
Male233441385010312269
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part1/Treatment Group A : 8mg QD INCB057643Part1/Treatment Group A : 12mg QD INCB057643Part1/Treatment Group A : 16mg QD INCB057643Part1/Treatment Group B : 8mg QD INCB057643Part1/Treatment Group B : 12mg QD INCB057643Part1/Treatment Group C : 8mg QD INCB057643Part2/Treatment Group A : 12 mg INCB057643 Expansion CohortPart2/Treatment Group B : 12 mg INCB057643 Expansion CohortPart3/Treatment Group A : 8 mg INCB057643 + Gemcitabine 1000mgPart3/Treatment Group B : 8 mg INCB057643 + Paclitaxel 80mgPart3/Treatment Group C : 8 mg INCB057643 + Rucaparib 600mgPart3/Treatment Group D : 8 mg INCB057643 + Abir +PredniPart3/Treatment Group E : 8 mg INCB057643 + Ruxolitinib 20mgPart3/Treatment Group F : 8 mg INCB057643 + Azacitidine 75mgEnrolled But Not DosedTotal
White/Caucasian3356407150143123111
Black/African American102100100110000016
Asian0000000000000000
American-Indian/Alaska Native0000001000000001
Native Hawaiian/Pacific Islander0100000000000001
Other0110112000000006
Missing0000001000000001
08

Study locations

18 sites
  • University of Alabama
    Birmingham, Alabama 35294-3300, United States
  • University of California
    La Jolla, California 92093, United States
  • Sarah Cannon Research Institute at Health One
    Denver, Colorado 80218, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Hematology - Oncology Associates of Treasure Coast
    Port Saint Lucie, Florida 34952, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University
    St Louis, Missouri 63110, United States
  • University of Rochester, Wilmot Cancer Center
    Rochester, New York 14642, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77030, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Institut Jules Bordet, Clinical Trial Conduct Unit
    Brussels, B-1000, Belgium
  • HÔPITAL SAINT-LOUIS, Service Hématologie Adultes
    Paris, 75010, France
09

References and documents

Publications

  • Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257. doi: 10.1158/1078-0432.CCR-18-4071. Epub 2019 Sep 16. PubMed 31527168 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Feb 2019, 32 months.

Results were first posted in Apr 2022, 3 years 2 months after primary completion. A results delay was requested in Feb 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2016
First posted
Mar 17, 2016
StartActual
May 18, 2016
Primary completionActual
Feb 13, 2019
CompletionActual
Feb 13, 2019
Results delay requested
Feb 12, 2020
Results first posted
Apr 28, 2022
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02711137
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 17, 2016
Start date
May 18, 2016
Primary completion
Feb 13, 2019
Completion
Feb 13, 2019
Results posted
Apr 28, 2022
Last update
Oct 21, 2025

Study contacts

Fred Zheng, MD, PhD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: INCB057643

Start the discussion